Clinical Safety Test of the Long Term Intake of Tabebuia Avellanedae (Taheebo) in Cancer Patients
10.1625/jcam.8.109
- VernacularTitle:悪性腫瘍患者におけるタベブイア・アベラネダエ（タヒボ）の長期摂取における臨床安全性試験
- Author:
Nobutaka SUZUKI
;
Takanari ARAI
;
Kazuo UEBABA
;
Masuo NAKAI
;
Riho SUZUKI
;
Yuko TAKIMOTO
- Publication Type:Journal Article
- Keywords:
cancer;
Tabebuia Avellanedae;
Taheebo;
safety;
clinical trial
- From:Japanese Journal of Complementary and Alternative Medicine
2011;8(2):109-118
- CountryJapan
- Language:Japanese
-
Abstract:
60 cancer patients between the ages of 20 and 80 who had completed a main treatment were randomly administered Tabebuia Avellanedae (Taheebo) extract 2.0 g/day (usual dosage), 4.0 g/day (2 times dosage), or 6.0 g/day (3 times dosage) for 6 months. A blood biochemical exam, urinalysis, adverse effects, several immunological parameters, urine 8-OHdG and QOLsurvey were evaluated. Five patients dropped out, but there was no direct cause and effect between the extract and dropout. Although several items of the blood biochemical exam revealed slight variation within the normal limits, distinct abnormities were not detected. Furthermore, side effects like allergic symptoms were not found. Immune parameters and urine 8-OHdG did not change significantly. CRP, which is a sensitive marker of inflammation, was significantly improved, and this may suggest the possibility of this extract helping to prevent hardening of blood vessels due to arteriosclerosis. In Japan, long-term food safety tests have rarely been done, therefore we recommend that more of these exams be carried out.
